SDAC: Clinical Trials Brown Bag Discussion Series

Title Date Presenter
The FDA's Final Rule on Expedited Safety Reporting: Implications for Data Monitoring of Clinical Trials Wednesday, October 5, 2016 - 12:00pm to 1:00pm

Robin Bechhofer

OSLER: An Open-Label Randomized Extension Trial of Evolocumab Wednesday, October 7, 2015 - 12:00pm

Marian Fisher

Electroconvulsive Therapy for Severe Depression Wednesday, September 9, 2015 - 12:00pm

Neil Baron

Conducting Valid Trials: the Critical (and Misunderstood) Roles of Randomization and Complete Follow-Up Wednesday, May 6, 2015 - 12:00pm to 1:00pm

Tom Cook

-- a preview of the workshop to be presented at SCT 2015

Clinical Trial Research in the Context of a Global Epidemic: Drug and Vaccine Studies for Ebola Virus Disease Wednesday, March 4, 2015 - 12:00pm to 1:00pm
Robin Bechhofer
Transparency, Sharing, and Reanalysis of Clinical Trial Data: Recent Publications Wednesday, February 4, 2015 - 12:00pm to 1:00pm
Melissa Schultz
Social Media and Crowdsourcing: A Consideration of Impacts on Clinical Trials and Health Research Wednesday, January 7, 2015 - 12:00pm to 1:00pm
Allison Furey
A Review of Analyses for Drug Induced Liver Injury Wednesday, December 17, 2014 - 12:00pm to 1:00pm
Gabriel Nicholas
STABILITY/SOLID TIMI-52 Darapladib Trials: Background, Results, and Monitoring Wednesday, November 12, 2014 - 12:00pm to 1:00pm
Scott Diegel
Mindfulness Meditation as an Intervention for Chronic Low Back Pain Wednesday, October 8, 2014 - 12:00pm to 1:00pm
John Kloke
Temporal Changes in Post-Discharge Risk among Patients Hospitalized for Heart Failure: An EVEREST Story Wednesday, September 3, 2014 - 12:00pm to 1:00pm
Ryan Zea

Abstract: Studies have shown patients suffering from a heart failure hospitalization are at higher risk for an adverse event in the first 90 days post-discharge. This claim has led to the conclusion of a vulnerable phase for these patients. The vulnerable phase hypothesis has ties to research, health care, and quality of care initiatives. However, as the case with chronic diseases, shouldn't risk continue to increase over time? A post-hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, may show just that.

The Study of Platelet Inhibition and Patient Outcomes (PLATO) Trial: Criticism and Responses Wednesday, May 14, 2014 - 12:00pm to 1:00pm

Brian Traver

Fish Oil: Benefits of Omega-3 Polyunsaturated Fatty Acids Wednesday, April 2, 2014 - 12:00pm to 1:00pm

Neil Baron

Everolimus: A mTOR Inhibitor for Treatment of Breast Cancer Wednesday, February 5, 2014 - 12:00pm to 1:00pm

Weiqun Tong

Adaptive Trials from 30,000 Feet Wednesday, January 8, 2014 - 12:00pm to 1:00pm

Tom Cook


Additional Information

Jeanne McCabe
Clinical Trials Program Manager
mccabe [at]